Caroline E. Ridgway

Maraviroc for Previously Treated Patients with R5 HIV-1 Infection

Roy M. Gulick, Jacob Lalezari, James Goodrich et al. · New England Journal of Medicine · 2008 · 741 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1

Gerd Fätkenheuer, Anton Pozniak, Margaret Johnson et al. · Nature Medicine · 2005 · 491 citations

Pharmacy, Pharmacology, Pharmacotherapy +14

Subgroup Analyses of Maraviroc in Previously Treated R5 HIV-1 Infection

Gerd Fätkenheuer, Mark Nelson, Adriano Lazzarin et al. · New England Journal of Medicine · 2008 · 361 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects

Deborah Russell, Lyndsey A. Whitlock, Caroline E. Ridgway et al. · British Journal of Clinical Pharmacology · 2008 · 98 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +13

Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers

Elna van der Ryst, M. Rosario, Caroline E. Ridgway et al. · British Journal of Clinical Pharmacology · 2008 · 89 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +11